



Fragment Screening on the FortéBio RED384 Instrument



Charles Wartchow, PhD
HTS Group
Roche Discovery Technologies, Nutley



Applications of FortéBio Fragment Detection in Drug Discovery



In progress

The Octet RED384 System



Integration with a plate handler
and a liquid dispensing station



Sensor tray and sample plates


FortéBio Small Molecule Detection 101




- **Detection**
 - White-light biolayer interferometry on a disposable fiber-optic surface
 - Microtiter plate (96 or 384)
 - No fluidics
- **Sensor preparation**
 - High density streptavidin sensor
 - *in-vivo* and *in-vitro* biotinylation of protein
 - On-line loading and off-line loading
- **Output**
 - Responses in association, dissociation
 - Small molecule kinetics (K_D , k_{on} , k_{off})
 - Binding profiles
 - Classical binding (Myszka's SPR studies, Analytical Biochem 2004)
 - Atypical binding (Gianetti et al J Med Chem 2008)
 - Non-binding
- **FortéBio RED384 Instrument**
 - 16-channels
 - reduced risk of sensor fouling/inactivation by problematic compound
 - Robot friendly
 - Run multiple plates
 - Throughput
 - 140 compounds + 16 positive controls + 16 negative controls in 62 minutes
 - Potentially advantageous for protein targets with stability issues
 - ~1000 compounds per day in a typical run with robotics

Bio-Layer Interferometry (BLI)


- A layer of molecules attached to the tip of an optic fiber creates an interference pattern at the detector
- A change in the number of molecules bound causes a measurable shift in the pattern



Interference spectrum




A Typical Experiment



ED Dissociation

Association



Instrument Validation Studies

- **Carbonic Anhydrase Model (SBS 2008, Wartchow et al. Poster P2072)**
 - Kinetic constants are similar to those reported for SPR (Myszka, Analytical Biochem 2004)
 - Detection limit is ~150 Daltons
 - Rmax correlates with molecular weight (R^2 0.9)
 - Small molecule signal for furosemide is predictable based on protein loading signal
 - Precision for responses is 10-15%
- **Hit Validation with multiple well-characterized targets**
 - PPI target and kinase target (SBS 2010, Podlaski et al., Poster B208)
 - Binding profiles and K_D s agree with Biacore T100 results
 - Good precision for K_D determinations
- **Fragment library Screening**
 - Carbonic anhydrase screen with the Maybridge Ro500 Library (SBS 2010, Wartchow et al., Poster B271)
 - 10 Hits, 5 confirmed
 - Minimal binding to reference sensor
 - PPI Targets 1,2 (SBS 2009, Li et al., Poster 7024)
 - 10% Hit rate, one hit validated by NMR
 - MW limit ~200Da
 - PPI Target 3 (SBS 2010, Podlaski et al., Poster B208)
 - 24% hit rate
 - Minimal binding to reference sensor
 - PPI Target 4
 - 3.4% hit rate

Octet RED Results with Carbonic Anhydrase Correlate to Biacore

Compound	ForteBio ¹	Biacore ^{2,3}
Acetazolamide (222 Daltons)	$K_D = 0.039 \mu\text{M}$ $k_{\text{on}} = 8.2\text{E}5 \text{ M}^{-1}\text{s}^{-1}$ $k_{\text{off}} = 0.033 \text{ s}^{-1}$	$K_D = 0.039, 0.019 \mu\text{M}$ $k_{\text{on}} = 3.0\text{E}6, 2.9\text{E}6 \text{ M}^{-1}\text{s}^{-1}$ $k_{\text{off}} = 0.079, 0.056 \text{ s}^{-1}$
Benzenesulfonamide (157 Daltons)	$K_D = 2.4 \mu\text{M}$ $k_{\text{on}} = 1.1\text{E}5 \text{ M}^{-1}\text{s}^{-1}$ $k_{\text{off}} = 0.26 \text{ s}^{-1}$	$K_D = 0.8, 0.85 \mu\text{M}$ $k_{\text{on}} = 1.7\text{E}5, 1.7\text{E}5 \text{ M}^{-1}\text{s}^{-1}$ $k_{\text{off}} = 0.12, 0.14 \text{ s}^{-1}$
Furosemide (330 Daltons)	$K_D = 1.2 \mu\text{M}$ $k_{\text{on}} = 6.4\text{E}4 \text{ M}^{-1}\text{s}^{-1}$ $k_{\text{off}} = 0.078 \text{ s}^{-1}$	$K_D = 1.0, 0.51 \mu\text{M}$ $k_{\text{on}} = 6.3\text{E}4, 9.7\text{E}4 \text{ M}^{-1}\text{s}^{-1}$ $k_{\text{off}} = 0.061, 0.05 \text{ s}^{-1}$
Sulpiride (341 Daltons)	$K_D = 239 \mu\text{M}$ $k_{\text{on}} = 3.9\text{E}3 \text{ M}^{-1}\text{s}^{-1}$ $k_{\text{off}} = 0.93 \text{ s}^{-1}$	$K_D = 48, 186 \mu\text{M}$ $k_{\text{on}} = 8.0\text{E}3, 3.4\text{E}3 \text{ M}^{-1}\text{s}^{-1}$ $k_{\text{off}} = 0.38, 0.64 \text{ s}^{-1}$

¹Wartchow et al., SBS 2008, Poster P2072


²Papalia et al., Analytical Biochem 359 (2006), 94-105

³Myszka, Analytical Biochem 329 (2004), 316-323


BLI results generally correlate with SPR



Kinase Target with a 238 Da compound




PPI Target with a 501 Da compound



Precision

Overlay of all sensorgrams



Conc (uM)	Average (nm)	SD (nm)
0	-0.009	0.010
4	0.022	0.010
20	0.078	0.015
100	0.167	0.014

4 concentrations x 6 replicates x 7 sensors = 168 analyses, $Z' = 0.64$




Variability includes well-to-well variability, and sensor-to-sensor variability

Podlaski, SBS 2010, Poster B208




Quantitative and Qualitative Assessment of Binding Profiles






Primary Hits



Atypical




Non-binders




Profiles are generally similar on Biacore

Characterization of PPI hits from a biochemical assay on RED384









- 28 compounds
- 6pt concentration series
- 3 h

Maybridge Ro3 500 Library Screen with Carbonic Anhydrase



Wartchow et al., SBS 2010, Poster B271

Steady-state Analysis of Confirmed Hits



- 10 Hits identified, 5 hits confirmed
- 3/5 compounds are sulfonamides
- Steady-state analysis is in agreement with Kinetic analysis
- *Wartchow et al., SBS 2010, Poster B271*

Recent Fragment Screen Results



- **PPI Target 4 with multiple binding sites, stability issue**
- **Method**
 - 200uM, N=1
 - 5% DMSO
 - 47 plates screened in 10 days
 - 0.9 mg protein (un-optimized)
- **FortéBio assay**
 - 3.5% primary hit rate
 - 3 scaffolds were observed repeatedly, one scaffold gave “atypical” binding profiles
 - 17% of primary hits were “atypical”
 - 11% of primary hits had responses >2X of positive control
 - 88% of primary hits are unique to FortéBio assay, and were not found in Biochemical assays
 - Confirmation *in progress*
 - 44% of primary hits were confirmed in a follow-up FortéBio assay (N=1)
 - 30% loss in activity noted for 2nd plate, normalization would increase hit rate
 - K_D cut-off at $460 \pm 153 \mu\text{M}$ (a conservative estimate, calculated from responses at the end of plates 1 and 2)
 - Responses on reference sensor noted for many hits
- **Overlap with biochemical assays**
 - Site 1: 52% overlap with FortéBio assay
 - Site 2: 38% overlap with FortéBio assay, atypical binders found

Summary

- **The FortéBio RED384 instrument is a valuable tool for drug discovery**
 - **General findings**
 - Highly reliable, robust (minimal maintenance, consistent responses over time, moderate sensitivity to RI mismatches)
 - Efficient tool for the identification of problematic compounds
 - Sensitivity is sufficient for small molecule characterization, and fragment detection
 - Throughput of 140 compounds/hr is advantageous for proteins with limited stability
 - 16-channel format reduces risk of run failure due to target inactivation
 - Improvements in sensitivity, precision will increase hit rate for low MW compounds and/or compounds with high K_D
 - Non-specific binding to the sensor is a minor issue, but can complicate analysis occasionally
 - Valuable tool for developing methods for new targets
 - **Hit Validation**
 - Kinetic constants and binding profiles generally correlate with Biacore results
 - **Fragment Screening**
 - A work in progress.....
 - Early results are promising
 - Complimentary to biochemical HTS

Acknowledgements

- **HTS Group**
 - *Kuo-Sen Huang*
 - *Frank Podlaski*
 - *Shirley Li*
 - *Karen Rowan*
 - *Xiaolei Zhang*
- **RDT**
 - *David Mark*
 - *David Fry*
 - *Shawn Walker*
 - *Jodi Arcuti*
 - *Rosita Feeley*
- **Compound management**
 - *Sevan Ibabecki*
 - *Janet Diratsaoglu*
 - *Peggy Borgese*
- **Protein Chemistry Group**
 - *Colin Garvie*
 - *Ueli Gubler*
- **FortéBio Inc**



We Innovate Healthcare